Dear Sir, Anticoagulation is necessary for hemodialysis (HD) therapy. As a standard, unfrac-tionated heparin (UFH) is administered comprising a mixture of different molecular weights (3-30 kD). For more than 10 years, low-molecular-weight heparins (LMWH, 4 kD) have been used [1,2] that comprise only the low-molecular-weight fractions of UFH. UFH induces a rise in TT3, FT3, TT4 [3, 4] and, depending on the assay, FT4 [5]. So far, data on the effect of LMWH on the levels of thyroid hormones in HD patients during HD are lacking. The aim of this study was to supply these data by a prospective longitudinal study that compared two short phases with UFH (pre-and postphase) to a 6-week LMWH phase in a double crossover design. The results were to be compared with those of Beyer [3] who was to our knowledge the only author to measure serially thyroid hormones during HD. Study design: During the prephase of 1 week, UFH (Thrombophob®; Nordmark, Germany) was administered in the usual do-sis for each patient (mean initial bolus of 3,500 IU, followed by an infusion with 800 IU/h, the infusion was stopped 1 h before the end of the HD session. In the LMWH phase lasting 6 weeks, Fragmin R (Kabi, Sweden) in 70% of the UFH dosis (mean bolus, 2,500 U, infusion with a mean of 550 U/h) was given. This dosage had been proven to be effective by measuring factor Xa and produced no side effects in 5 patients of a pilot study before this study. In the postphase, UFH was administered at each session for 1 week. Blood was drawn each hour of each session in the preand postphase and each week in the LMWH phase. Twelve stable chronical HD patients (4 women, 8 men) who had been on HD for at least half a year were examined after informed consent. Median age was 51 years, range 25-76. Mean dry body weight was 63.4 kg, and mean interdia-lytic weight gain 2.7 kg. The mean albumin level was 4.3 g/dl. TT3, TT4 and FT4 were measured by radioimmunoassay with an indirect method using low-affinity monoclonal antibodies in coated tubes (SPAC T3 and SPAC T4/FT4 by Byk-Mallinckrodt, Germany). The reference ranges were: T3, 80-220 ng/dl; T4,4.5-12.5 µg/dl and FT4 0.6-1.8 ng/ dl. For calculation the LMWH phase was divided in two so that four blocks resulted: UFH prephase,
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